Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company’s mission of connecting innovation to purpose. Dr. Brake will build upon Corbus’ commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation. Dr. Brake formerly held leadership roles at Takeda Oncology, including Vice President, Global Project Leader in the Oncology Therapeutic Area and Head, U.S. Medical Affairs, Oncology Business Unit. Read more >>